Clene Inc. Stock Rises Ahead of Investor Call
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 03 Dec 25
Source: Investing
Clene Inc. shares surged by 37.37% as it crossed above the 5-day SMA, reflecting positive investor sentiment ahead of an important investor call.
The company plans to provide updates on its CNM-Au8 program for ALS on December 3, 2025, which is expected to enhance investor confidence and interest in its innovative therapies.
This upcoming call highlights Clene's commitment to transparency and engagement with investors, potentially attracting more attention to its promising developments in the biopharmaceutical sector.
Analyst Views on CLNN
Wall Street analysts forecast CLNN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLNN is 30.40 USD with a low forecast of 30.00 USD and a high forecast of 31.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.170
Low
30.00
Averages
30.40
High
31.00
Current: 4.170
Low
30.00
Averages
30.40
High
31.00
About CLNN
Clene Inc. is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson's disease, and multiple sclerosis. It specializes in the discovery, development, and commercialization of clean-surfaced nanotechnology (CSN) therapeutics. CNM-Au8, the lead asset, is a concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals. CNM-Au8’s mechanism of action targets mitochondrial dysfunction by catalyzing the production of nicotinamide adenine dinucleotide. Its CNM-ZnAg is a broad-spectrum antiviral, antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions under development to treat infectious disease and to provide immune support for symptom resolution. Its CNM-AgZn17 is a gel polymer suspension of Zn2+ and Ag+ under development for the treatment of infectious diseases and to support wound healing.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
